Bioceltix Past Earnings Performance
Past criteria checks 0/6
Bioceltix's earnings have been declining at an average annual rate of -40.7%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-40.7%
Earnings growth rate
-31.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -37.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Bioceltix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -16 | 16 | 0 |
| 30 Jun 24 | 0 | -16 | 17 | 0 |
| 31 Mar 24 | 0 | -15 | 16 | 0 |
| 31 Dec 23 | 0 | -14 | 14 | 0 |
| 30 Sep 23 | 0 | -13 | 12 | 0 |
| 30 Jun 23 | 0 | -12 | 11 | 0 |
| 31 Mar 23 | 0 | -10 | 9 | 0 |
| 31 Dec 22 | 0 | -9 | 8 | 0 |
| 30 Sep 22 | 0 | -8 | 7 | 0 |
| 31 Mar 22 | 0 | -5 | 5 | 0 |
Quality Earnings: XI3 is currently unprofitable.
Growing Profit Margin: XI3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if XI3's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare XI3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XI3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: XI3 has a negative Return on Equity (-37.76%), as it is currently unprofitable.